GLP-1 Weight-Loss Drugs Linked to Lower Cancer Risk and Mortality in New Studies
At ASCO's annual meeting, several studies suggest GLP-1 weight-loss drugs may reduce cancer risk and improve outcomes: in 110,000 women, a 30% lower incidence of breast cancer; in 27,000 breast cancer patients, a 30% lower risk of death when added to standard treatment; and in 12,000 patients with multiple cancers, a 38–50% lower likelihood of progressing to stage IV. The findings are observational and not yet definitive; more research is needed to determine whether benefits come from weight loss or direct anti-cancer effects, though anti-inflammatory and immune-modulatory mechanisms are plausible.